Filing Flows

Filing Flows › Avalo Therapeutics (AVTX) › Next earnings date

Avalo Therapeutics (AVTX) earnings: beat the estimate

Avalo Therapeutics (AVTX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.34 against −$0.55 (+38.0%). It beat the EPS estimate in 60% of the quarters on record.

Last result+38.0% vs estimate
Beat rate60%

The last report

Avalo Therapeutics reported revenue of $59K for the fourth quarter 2025 (-69% Y/Y), net loss $13.7M. How it makes money → · Every quarter →

Avalo Therapeutics: EPS against the estimate, last 5 reportsAvalo Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$1.64−$2.19Nov 25−$1.50−$0.37Mar 26−$1.07−$0.98May 26−$0.62−$0.83Aug 26−$0.55−$0.34Nov 26
Latest (Nov 26): Estimate −$0.55, Reported −$0.34.
AVTX: the stock's move on each reportAVTX: the stock's move on each reportAug 6, 2026-2.8%May 13, 2026-4.7%Mar 23, 2026+0.2%Nov 6, 2025-8.5%

Avalo Therapeutics' latest quarter

Avalo Therapeutics, Q4 2025: revenue $59K (-69% year over year), net loss $13.7M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Avalo Therapeutics beat earnings?

Avalo Therapeutics (AVTX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.34 against −$0.55 (+38.0%).

When does AVTX report earnings?

The next date is not set yet.

Does Avalo Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.